"As we had imagined and hoped, Keytruda has proved to be foundational for the treatment of lung cancer," says Roger Perlmutter, the research head at Merck. "The question that will be addressed by oncologists of the future will be: In which individuals does one decide to use monotherapy Keytruda?"
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2018/06/03/merck-wins-again/
via IFTTT
No comments:
Post a Comment